Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03080974 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 1, 2025 to Jun 1, 2028
    • Study completion date: Apr 1, 2026 to Apr 1, 2029
    v13
  2. Re-verified, no change to tracked fieldsv12
  3. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v11
  4. 2 versions Re-verified since Oct 6, 2021, no change to tracked fieldsv9-v10
  5. Primary completion date: Jun 1, 2021 to Jun 1, 2025
    • Study completion date: Apr 1, 2022 to Apr 1, 2026
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v7
  2. Study description expanded, about 1 wordv6
  3. Start date changed from estimate of Oct 1, 2017 to Aug 14, 2017v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 1, 2017 to Oct 1, 2017
    • Site details revised
    v4
  5. Start date: Jun 1, 2017 to Jul 1, 2017
    • Study sites: 0 to 1
    v3
  6. Start date: Apr 1, 2017 to Jun 1, 2017
    • Primary endpoint revised
    • Primary completion date: Apr 1, 2021 to Jun 1, 2021
    • Secondary endpoints: 1 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Trial Details
NCT Number NCT03080974
Lead Sponsor University of Louisville
Conditions
(from sponsor)		 Pancreatic Adenocarcinoma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov